Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

GenomtecTumor

Financiado

MicroRNA based tool for non invasive early stage cancer diagnosis

The goal of this project is to develop a portable and easy to use device for early cancer diagnosis to maximise patient outcomes. Cancer is a major public health problem and a leading cause of morbidity and death with over 14.1 mi... ver más

30/04/2020

Genomtec S.A.

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

GENOMTEC SPOLKA AKCYJNA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-04-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 6 años

0% 100%

2 Participantes

Genomtec S.A.

50.00K€ | Lider

HOME 24 POR 7

493.76K€ | Participante

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 4 meses Fecha Inicio: 2019-12-03
Fecha Fin: 2020-04-30

Líder del proyecto

GENOMTEC SPOLKA AKCYJNA

TRL 4-5

Presupuesto del proyecto 71K€

Descripción del proyecto The goal of this project is to develop a portable and easy to use device for early cancer diagnosis to maximise patient outcomes. Cancer is a major public health problem and a leading cause of morbidity and death with over 14.1 million cases reported worldwide every year. Early cancer diagnosis is critical to its successful treatment, yet today’s technologies are limited in their accuracy, and are laborious and time consuming processes. Genomtec aims to address this challenge with its novel diagnostic system based on unique, patent pending amplification technology – Streamlined Nucleic Acid Amplification Technology (SNAATTM). Genomtec’s programme is built on many years of R&D activity and collaborative projects with academic and medical institutions in Poland. Using this robust molecular biology method for real-time amplification of nucleic acids, Genomtec’s cancer diagnostic test can be performed in 20 minutes at the point-of-care. Genomtec offers the possibility to accurately diagnose cancer early and reduce its financial burden on the economy by enabling more effective treatment and improved patient outcomes, including increased patient survival, increased post-treatment quality of life, and reduced patient distress during the diagnostic phase. Genomtec’s diagnostic device is unique and there are no competitors using the same molecular approach to diagnose cancer based on detection of tumour specific microRNA. The ultimate success of this project will depend on the generation of clinical data which will improve opportunities for sales expansion. Genomtec plans to apply for the SME Phase 2 grant to take its product through device finalisation, clinical studies, and establishment of the distribution network. Genomtec has an established business development contact network and has been awarded numerous prizes for its innovativeness and potential for growth, e.g. The best non-US startup at Boston HUBWeek in October 2018.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores